Pancreatic Cancer Research

ResearcherUniversity Hospitals of Leicester NHS TrustNo recent work listed

Matthew S. Metcalfe

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5112874460. Sources: ClinicalTrials.gov.

Their work

Papers
11
Trials
1
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 2 papers · 2012: none · 2013: 3 papers · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers

Papers 11

  1. Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intrave… Co-author DOI 10.21037/atm.2020.02.02↗
  2. Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Intravenous Omega 3 Compared with Controls Co-author DOI 10.21203/rs.3.rs-36878/v1↗
  3. Treatment Access and Survival Amongst British Asians with Pancreatic Cancer. Co-author DOI 10.1007/s00268-016-3707-7↗
  4. Pancreatic cancer tissue banks: where are we heading? Co-author DOI 10.2217/fon-2016-0243↗
  5. Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.clnu.2013.09.017↗
  6. Restoration of mannose-binding lectin complement activity is associated with improved outcome in patients with advanced pancreatic cancer treated with gemcitab… Co-author DOI 10.1177/0148607113476304↗
  7. The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. Co-author DOI 10.1007/s10620-013-2778-7↗
  8. Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e3182124216↗
  9. Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with g… Co-author DOI 10.1111/hpb.12002↗
  10. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. Co-author DOI 10.1007/s00268-011-0984-z↗
  11. Potential applications of fish oils rich in n-3 fatty acids in the palliative treatment of advanced pancreatic cancer. Co-author DOI 10.1017/s0007114511003060↗

Trials 1

  1. A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer Study chair NCT01019382↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ashley Robert Dennison · 10 shared papers, 1 shared trial, 2009–2020 · strength 0.62
  2. William P. Steward · 6 shared papers, 1 shared trial, 2009–2020 · strength 0.43
  3. Ali Raza Arshad · 7 shared papers, 2011–2020 · strength 0.42
  4. John Isherwood · 5 shared papers, 2014–2020 · strength 0.39
  5. Wen Yuan Chung · 5 shared papers, 2013–2020 · strength 0.35
  6. Franscois Runau · 2 shared papers, 2020 · strength 0.20
  7. Giuseppe Garcea · 2 shared papers, 2011–2017 · strength 0.12
  8. Vickna Balarajah · 1 shared paper, 2016 · strength 0.05
  9. Abu Z M Dayem Ullah · 1 shared paper, 2016 · strength 0.05
  10. Bilal A. Al-Sarireh · 1 shared paper, 2016 · strength 0.05
  11. Brian Ritchie Davidson · 1 shared paper, 2016 · strength 0.05
  12. Claude Chelala · 1 shared paper, 2016 · strength 0.05
  13. Hemant Mahendrakumar Kocher · 1 shared paper, 2016 · strength 0.05
  14. Mohammad Abu Hilal · 1 shared paper, 2016 · strength 0.05
  15. Andrew R. Hart · 1 shared paper, 2013 · strength 0.03
  16. Frank J. Carey · 1 shared paper, 2013 · strength 0.03
  17. Allan Clark · 1 shared paper, 2013 · strength 0.03
  18. D. P. Berry · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.